Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker OCUL · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patien… NCT05335122 · Open Angle Glaucoma, Ocular Hypertension OTX-TIC low dose Travoprost Intracameral Implant, OTX-TIC h… | OCUL Ocular Therapeutix, Inc. | Phase 2 | Completed | 83 | Jan 24, 2024 | Registry ↗ |
| Jul 1, 2026 | Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With… NCT07516132 · Neovascular Age-Related Macular Degeneration (nAMD) OTX-TKI | OCUL Ocular Therapeutix, Inc. | Phase 3 | Recruiting | 850 | Aug 1, 2030 | Registry ↗ |
| Mar 16, 2026 | A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-… NCT07235085 · Non-Proliferative Diabetic Retinopathy Single intravitreal injection of axitinib hydrogel implant… | OCUL Ocular Therapeutix, Inc. | Phase 3 | Recruiting | 930 | Mar 2027 | Registry ↗ |
| Jun 17, 2025 | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects Wi… NCT06495918 · Neovascular Age-related Macular Degeneration OTX-TKI, Aflibercept | OCUL Ocular Therapeutix, Inc. | Phase 3 | Active, not recruiting | 825 | Jan 8, 2027 | Registry ↗ |
| Apr 18, 2025 | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Im… NCT06223958 · Neovascular Age-Related Macular Degeneration OTX-TKI (axitinib implant), Aflibercept | OCUL Ocular Therapeutix, Inc. | Phase 3 | Active, not recruiting | 344 | Apr 29, 2026 | Registry ↗ |
| Oct 1, 2024 | CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypert… NCT04360174 · Ocular Hypertension, Open Angle Glaucoma OTX-TIC | OCUL Ocular Therapeutix, Inc. | Phase 1 | Completed | 19 | May 24, 2021 | Registry ↗ |
| Jul 10, 2024 | OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED) NCT05814757 · Dry Eye Syndromes, Eye Diseases OTX-DED, Controlled Insertion | OCUL Ocular Therapeutix, Inc. | Phase 2 | Completed | 100 | May 22, 2024 | Registry ↗ |
| Jul 10, 2024 | CLN-0046: Treatment of AMD Subjects With OTX-TKI NCT03630315 · Neovascular Age-related Macular Degeneration OTX-TKI, OTX-TKI | OCUL Ocular Therapeutix, Inc. | Phase 1 | Completed | 29 | Jan 10, 2024 | Registry ↗ |
| Apr 15, 2024 | A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflamm… NCT04539548 · Cataract Dextenza Ophthalmic Insert, Prednisolone acetate ophthalmic… | OCUL Ocular Therapeutix, Inc. | Phase 3 | Completed | 65 | Dec 21, 2023 | Registry ↗ |
| Jan 26, 2024 | Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degener… NCT04989699 · Neovascular Age-Related Macular Degeneration OTX-TKI/Sham, Aflibercept/Sham | OCUL Ocular Therapeutix, Inc. | Phase 1 | Completed | 21 | Feb 6, 2023 | Registry ↗ |
| Dec 8, 2023 | Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Sev… NCT05695417 · Non-proliferative Diabetic Retinopathy OTX-TKI, Sham | OCUL Ocular Therapeutix, Inc. | Phase 1 | Unknown | 21 | Jan 2024 | Registry ↗ |
| Nov 14, 2023 | Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Diseas… NCT04362670 · Dry Eye Disease OTX-CSI, Placebo Vehicle | OCUL Ocular Therapeutix, Inc. | Phase 1/2 | Completed | 153 | Aug 11, 2021 | Registry ↗ |
| Jun 9, 2023 | A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular… NCT04061044 · Open Angle Glaucoma and Ocular Hypertension Ophthalmic Insert | OCUL Ocular Therapeutix, Inc. | Phase 3 | Completed | 40 | Feb 10, 2020 | Registry ↗ |
| Feb 22, 2023 | To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of… NCT04747977 · Dry Eye OTX-DED, OTX-DED | OCUL Ocular Therapeutix, Inc. | Phase 2 | Completed | 172 | Aug 11, 2021 | Registry ↗ |
| Feb 6, 2023 | A Human Factors Study to Evaluate a Novel Intracanalicular Insertion Device in Healthy Subjects NCT04945824 · Healthy Dexamethasone Ophthalmic, Dilator | OCUL Ocular Therapeutix, Inc. | Early phase 1 | Terminated | 2 | Nov 1, 2022 | Registry ↗ |
| Sep 16, 2022 | An Observational, Qualitative Study Assessing Eye Drop Administration NCT05307081 · Ocular Injury Artificial Tears | OCUL Ocular Therapeutix, Inc. | — | Unknown | 300 | Jul 2023 | Registry ↗ |
| Oct 19, 2021 | Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain A… NCT01666210 · Ocular Inflammation and Pain OTX-DP (Dexamethasone punctum plug), Placebo Vehicle Punctu… | OCUL Ocular Therapeutix, Inc. | Phase 2 | Completed | 60 | Aug 2013 | Registry ↗ |
| Oct 11, 2021 | Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT NCT02914509 · Open Angle Glaucoma, Ocular Hypertension Travoprost, Placebo Vehicle | OCUL Ocular Therapeutix, Inc. | Phase 3 | Completed | 565 | Mar 30, 2019 | Registry ↗ |
| Oct 7, 2021 | A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis NCT04050865 · Allergic Conjunctivitis Dexamethasone, 0.4mg, Placebo plug with no drug | OCUL Ocular Therapeutix, Inc. | Phase 3 | Completed | 96 | Feb 28, 2020 | Registry ↗ |
| Sep 29, 2021 | I-ZIP Ocular Bandage Pivotal Study NCT00774228 · Cataract I-ZIP Ocular Bandage, Oasis 24 Hour Soft Shield Collagen Co… | OCUL Ocular Therapeutix, Inc. | Not applicable | Completed | 420 | Jul 2009 | Registry ↗ |
| Oct 12, 2020 | OTX-15-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chron… NCT02988882 · Chronic Allergic Conjunctivitis Dexamethasone, Placebo Vehicle | OCUL Ocular Therapeutix, Inc. | Phase 3 | Completed | 86 | Apr 27, 2016 | Registry ↗ |
| Feb 5, 2020 | OTX-14-002: Device Exposure Registry NCT02309736 · Endophthalmitis ReSure Sealant | OCUL Ocular Therapeutix, Inc. | — | Withdrawn | 0 | Apr 2020 | Registry ↗ |
| Jan 31, 2020 | Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pai… NCT02034019 · Post Ocular Surgical Inflammation and Pain Dexamethasone, Punctum Plug | OCUL Ocular Therapeutix, Inc. | Phase 3 | Completed | 247 | Dec 2014 | Registry ↗ |
| Sep 26, 2019 | OTX-14-003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocula… NCT02089113 · Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation Dexamethasone, Placebo Vehicle | OCUL Ocular Therapeutix, Inc. | Phase 3 | Completed | 241 | Jan 2015 | Registry ↗ |
| Sep 11, 2019 | OTX-14-001: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chron… NCT02062905 · Chronic Allergic Conjunctivitis Dexamethasone, Placebo Vehicle | OCUL Ocular Therapeutix, Inc. | Phase 2 | Completed | 68 | Aug 2014 | Registry ↗ |
| Mar 29, 2018 | OTX-14-006: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Dry E… NCT02468700 · Dry Eye Dexamethasone, Placebo Vehicle | OCUL Ocular Therapeutix, Inc. | Phase 2 | Completed | 43 | Aug 2015 | Registry ↗ |
| Mar 29, 2018 | OTX-14-007: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chron… NCT02445326 · Chronic Allergic Conjunctivitis Dexamethasone, Placebo Vehicle | OCUL Ocular Therapeutix, Inc. | Phase 3 | Completed | 73 | Aug 2015 | Registry ↗ |
| Nov 13, 2017 | OTX-15:003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocula… NCT02736175 · Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation Dexamethasone, Placebo Vehicle | OCUL Ocular Therapeutix, Inc. | Phase 3 | Completed | 438 | May 2016 | Registry ↗ |
| Dec 14, 2016 | Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment… NCT02312544 · Glaucoma, Ocular Hypertension OTX-TP, Timolol | OCUL Ocular Therapeutix, Inc. | Phase 2 | Completed | 72 | Sep 2015 | Registry ↗ |
| Dec 12, 2016 | Multi-Arm Feasibility Study Evaluating OTX-TP Compared to Timolol in Treatment of Subjects With Ope… NCT01845038 · Glaucoma OTX-TPa ~4µg/day over 2 mos. with natural tears drops, OTX-… | OCUL Ocular Therapeutix, Inc. | Phase 1 | Completed | 41 | Mar 2014 | Registry ↗ |
| Dec 12, 2016 | ReSure Sealant Pivotal Study NCT01498224 · Cataract Surgery Incision Leak ReSure Sealant, Sutures | OCUL Ocular Therapeutix, Inc. | Phase 3 | Completed | 488 | Nov 2012 | Registry ↗ |
| Dec 5, 2016 | ReSure Sealant Post Approval Study NCT02310815 · Adverse Events ReSure Sealant | OCUL Ocular Therapeutix, Inc. | — | Completed | 626 | Feb 2016 | Registry ↗ |
| Feb 11, 2016 | Non-Significant Risk Feasibility Study to Assess Retention and Replacement of the OTX Punctum Plug NCT01800175 · Healthy Subjects Punctum Plug | OCUL Ocular Therapeutix, Inc. | Phase 1 | Unknown | 60 | Dec 2016 | Registry ↗ |
33 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:20 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances